JP2018065829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018065829A5 JP2018065829A5 JP2017225061A JP2017225061A JP2018065829A5 JP 2018065829 A5 JP2018065829 A5 JP 2018065829A5 JP 2017225061 A JP2017225061 A JP 2017225061A JP 2017225061 A JP2017225061 A JP 2017225061A JP 2018065829 A5 JP2018065829 A5 JP 2018065829A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- subject
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 208000001613 Gambling Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 206010021567 Impulsive behaviour Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- -1 hydrate Substances 0.000 claims 2
- 230000001771 impaired Effects 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010060891 General symptom Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
Claims (9)
- 対象において統合失調症の少なくとも１種類の、課題完了の問題、気分の問題、気分変調、非定型的抗精神病薬による処置に起因する静座不能、非定型的抗精神病薬による処置に起因する錐体外路系症状、および肥満からなるグループから選択される陰性症状を処置または緩和するための医薬組成物であって、式（ＩＩ）の化合物：
- 一日当たりの用量が１６〜６４ｍｇである請求項１に記載の医薬組成物。
- 一日当たりの用量が３２〜６４ｍｇである請求項１に記載の医薬組成物。
- 対象において統合失調症の少なくとも１種類の、障害された思考、衝動的行動、幻覚、ギャンブル依存、アルコール依存、および不安からなるグループから選択される陽性症状を処置または緩和するための医薬組成物であって、式（ＩＩ）の化合物：
- 一日当たりの用量が１６〜６４ｍｇである請求項４に記載の医薬組成物。
- 一日当たりの用量が３２〜６４ｍｇである請求項４に記載の医薬組成物。
- 認知の問題、記憶の問題、運動速度の問題、言語の流暢さの問題、処理速度の問題、睡眠の問題、障害された思考、衝動的行動、幻覚、ギャンブル依存、アルコール依存、および不安からなるグループから選択される少なくとも一種類の統合失調症の陽性および／または一般症状の処置をさらに含む、請求項１〜３のいずれかに記載の医薬組成物。
- 化合物が低いＱＴ延長傾向を有する、請求項１〜３又は７のいずれかに記載の医薬組成物。
- 治療の経過中に化合物が低いＱＴ延長傾向を有する、請求項４〜６のいずれかに記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| US61/366,080 | 2010-07-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016135208A Division JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018065829A JP2018065829A (ja) | 2018-04-26 |
| JP2018065829A5 true JP2018065829A5 (ja) | 2018-07-05 |
| JP6419294B2 JP6419294B2 (ja) | 2018-11-07 |
Family
ID=45497167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Pending JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2016135208A Pending JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2017225061A Active JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Pending JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2016135208A Pending JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130274290A1 (ja) |
| EP (2) | EP2595485B1 (ja) |
| JP (3) | JP2013531073A (ja) |
| KR (1) | KR101867634B1 (ja) |
| CN (2) | CN107007603A (ja) |
| BR (1) | BR112013001302A2 (ja) |
| CA (2) | CA2805904C (ja) |
| DK (1) | DK2595485T3 (ja) |
| ES (1) | ES2914120T3 (ja) |
| HU (1) | HUE058736T2 (ja) |
| PL (1) | PL2595485T3 (ja) |
| PT (1) | PT2595485T (ja) |
| RU (2) | RU2746871C2 (ja) |
| TW (1) | TWI520949B (ja) |
| WO (1) | WO2012012543A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| CA2968977A1 (en) * | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| SG10202011470UA (en) * | 2016-05-25 | 2021-01-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| UA127349C2 (uk) | 2017-06-21 | 2023-07-26 | Мінерва Ньюросаєнсиз, Інк. | Кишковорозчинна лікарська форма для перорального застосування з контрольованим вивільненням |
| EP3840835A1 (en) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| US20230190870A1 (en) | 2020-05-20 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Method for Treating Lysosomal Storage Diseases with Histatin Peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
| ZA908641B (en) * | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| DK0637306T3 (da) * | 1992-04-23 | 2001-07-30 | Merrell Pharma Inc | 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi |
| DE60129210T2 (de) * | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | Zyklische amid-derivate |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en active Application Filing
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active IP Right Grant
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018065829A5 (ja) | ||
| JP2016199578A5 (ja) | ||
| JP2018140982A5 (ja) | ||
| JP2015505564A5 (ja) | ||
| JP2017149726A5 (ja) | ||
| JP2018021046A5 (ja) | ||
| JP2017057230A5 (ja) | ||
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2015187156A5 (ja) | ||
| JP2016518337A5 (ja) | ||
| JP2017514910A5 (ja) | ||
| JP2015522589A5 (ja) | ||
| JP2016510326A5 (ja) | ||
| JP2018529742A5 (ja) | ||
| JP2016531885A5 (ja) | ||
| JP2020529995A5 (ja) | ||
| JP2013531073A5 (ja) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2014058509A5 (ja) | ||
| RU2014151161A (ru) | Метаболиты (1r-транс)-n-[[2-(2,3-дигидро-4-бензофуранил)циклопропил]-метил]пропанамида | |
| JP2014518280A5 (ja) | ||
| JP2016533367A5 (ja) | ||
| JP2017508004A5 (ja) | ||
| JP2015524460A5 (ja) |